trending Market Intelligence /marketintelligence/en/news-insights/trending/_9pV34vlu5t1Ahp-j6-kag2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bavarian Nordic to sell priority review voucher to unknown buyer for $95M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Bavarian Nordic to sell priority review voucher to unknown buyer for $95M

Bavarian Nordic A/S has agreed to sell a priority review voucher that was obtained through the development of a smallpox and monkeypox vaccine for $95 million in cash.

The Danish biotechnology company did not disclose the buyer. The transaction is subject to customary closing conditions including antitrust review, which is expected to occur in early 2020.

The U.S. Food and Drug Administration granted Bavarian Nordic the priority review voucher in September upon the approval of the smallpox and monkeypox vaccine Jynneos.

Holders of priority review vouchers are granted accelerated review from the FDA for future human drug applications.

Jefferies International Ltd. served as the exclusive financial adviser to Bavarian Nordic for the sale.